Gil Labrucherie, CFA, JD, is the Chief Financial Officer at Septerna. Mr. Labrucherie is a seasoned executive with over 25 years of experience in strategic leadership roles across the biotechnology and technology sectors, with expertise in corporate finance, business development, and legal affairs.
Prior to joining Septerna, Mr. Labrucherie served as Chief Financial Officer at ACELYRIN, a publicly traded late-stage clinical biopharma company, where he later expanded his role to include Chief Business Officer responsibilities. Previously, he spent 17 years at Nektar Therapeutics, serving most recently as Chief Financial Officer and Chief Operating Officer while previously serving as Nektar’s Senior Vice President, General Counsel and Secretary. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, where he specialized in global corporate alliances and mergers and acquisitions. He began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati.
Mr. Labrucherie currently serves on the board of directors of Rezolute, Inc., a publicly traded late-stage biopharmaceutical company. He received his JD from the University of California Berkeley School of Law and his BA from the University of California, Davis. Mr. Labrucherie is a CFA charterholder and a member of the State Bar of California.